When was Isabl founded?

Isabl was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Isabl located?

Isabl is headquartered in New York City, United States. It is registered at Brooklyn, New York.

Who is the current CEO of Isabl?

Elli Papaemmanuil of Isabl. They have also founded 1 company.

How many employees does Isabl have?

As of Mar 31, 2026, the latest employee count at Isabl is 8.

Is Isabl a funded company?

Isabl is a funded company, having raised a total of $3M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2022.

When was the latest funding round of Isabl?

Isabl's latest funding was a $***** Grant (prize money) round on Apr 01, 2023, with participation from 1 investor.

Where does Isabl rank among its competitors?

Isabl ranks 126th amongst 395 active competitors, of which 128 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Isabl?

Isabl's top competitors include Juno Therapeutics, Personalis and Caris Life Sciences. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Isabl - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a medical diagnosis platform to analyze genome of cancer patients. It offers Isabl GxT platform that analyzes the genome and transcriptome to identify mutations, disease surveillance and biomarker discovery.

Website: www.isabl.io/
Social
Email ID: *****@isabl.io
Registered Address: Brooklyn, New York

Key Metrics

Founded Year

2020

Location

New York City, United States

Stage

Seed

Total Funding

$3M in 2 rounds

Latest Funding Round

Grant (prize money), Apr 01, 2023, $*****

Investors

Evolution VC Partners & 7 more

Ranked

126^th among 395 active competitors

Employee Count

8 as on Mar 31, 2026

Similar Companies

Juno Therapeutics & 540 more

View Isabl's full profile

Isabl is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Isabl, Inc CIN: 84-3862631 , United States, Active	Dec 31, 2017	-	-	-
ISABL CIN: 843862631 , United States, Active	Dec 31, 1999	-	3 (As on Dec 31, 2024)	-

Isabl has raised a total funding of $3M over 2 rounds. Its first funding round was on 2022. Its latest funding round was a Grant (prize money) round on Apr 01, 2023 for $*****. 1 investor participated in its latest round. Isabl has 7 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Isabl:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2023	4677464	Grant (prize money)	1973785	9347377	3767200	7111281
2022	9765	Seed	9045	7137	9861	Box 1 & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Isabl's funding rounds and investors

The founders of Isabl are Andrew Kung, Elli Papaemmanuil and Juan Medina. Elli Papaemmanuil is the CEO of Isabl.

Here are the details of Isabl's key team members:

Andrew Kung: Co-Founder, Board of Directors of Isabl.
Elli Papaemmanuil: Co-Founder & CEO of Isabl.
Contact Info: 1 email address
Juan Medina: Co-Founder and CTO of Isabl.

View details of Isabl's Founder profiles and Board Members

Isabl's employee count trend

Isabl has 8 employees as of Mar 26. Here is Isabl's employee count trend over the years:

Uncover Isabl's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Isabl include Juno Therapeutics, Personalis and Caris Life Sciences. Here is the list of Top 10 competitors of Isabl, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
2nd	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 4 others	73/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	72/100
4th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Advent Life Sciences, Foresite Capital & 11 others	70/100
5th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
6th	Castle Biosciences 2008, Friendswood (United States), Public	Provider of diagnostic devices for treating cancer	$62M	Industry Ventures, Health Quest Capital & 9 others	70/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Third Rock Ventures & 9 others	70/100
8th	Congenica 2013, Cambridge (United Kingdom), Acquired	Provider of a platform for clinical genome analytics for treating patients with genetic diseases	$81.9M	Tencent, IDO Investments & 39 others	69/100
9th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	68/100
10th	NeoGenomics 2002, Fort Myers (United States), Public	Provider of cancer genetic diagnostic services	-	Ranger Investments, Aspen Capital & 1 others	66/100
126th	Isabl 2020, New York City (United States), Seed	Developer of a medical diagnosis platform to analyze genome of cancer patients	$3M	Evolution VC Partners, Two Sigma Ventures ... & 6 others	42/100